GlassScriptPhysician profile
Grissel Rios
NPI 1821072935
$12,772.22
in general payments reported to CMS, 2019-2025
22 companies · $4,203 in 2025
The $4,203 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $55.93 · 2021: $94.16 · 2022: $387 · 2023: $548 · 2024: $6,941 · 2025: $4,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,864 · Food and Beverage: $2,687 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,863.62 |
| Food and Beverage | $2,686.51 |
| Education | $141.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $8,146.25 | 2024-2025 | |
| Argenx US, INC. | $1,704.60 | 2025 | Vyvgart Hytrulo |
| Abbvie INC. | $744.31 | 2019-2025 | Rinvoq |
| Amgen INC. | $462.75 | 2019-2024 | Tavneos, Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $328.86 | 2019-2025 | Orencia, Sotyktu |
| Janssen Pharmaceuticals, INC | $178.44 | 2022-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $157.41 | 2022-2025 | Acthar |
| Ucb, INC. | $137.66 | 2019-2025 | Bimzelx, Cimzia |
| United Therapeutics Corporation | $122.79 | 2023 | |
| Glaxosmithkline, LLC. | $114.46 | 2024-2025 | Benlysta |
| Merck Sharp & Dohme LLC | $113.45 | 2025 | Winrevair |
| Celgene Corporation | $104.09 | 2024 | |
| Janssen Biotech, INC. | $100.14 | 2025 | Tremfya |
| Actelion Pharmaceuticals US, INC. | $89.99 | 2025 | Uptravi, Opsumit |
| Eli Lilly Export S.A. Puerto Rico Branch | $58.36 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $49.40 | 2019-2021 | |
| Radius Health, INC. | $41.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.83 | 2023 | Cyltezo |
| Sanofi-Aventis U.S. LLC | $24.00 | 2019 | |
| Genzyme Corporation | $23.97 | 2019 | |
| Genentech, INC. | $23.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grissel Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.